Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 31, 2026Journal of Thrombosis and ThrombolysisOpen Access

AI and multi-modality models modernize cardiotoxicity detection to protect patients in oncology care.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Resource constraints in regulatory agencies like the FDA threaten cardiotoxicity safety oversight, creating a need to outline public-private partnerships, collaborative oversight models, and advanced technologies to modernize surveillance.

Design

Review and framework proposal

Key result

Artificial intelligence and multi-modality collaborative models can modernize cardiotoxicity detection, protect patients, and sustain benefits in oncology care.

Authors

RBRichard C. Becker

Discussion

Loading...

Member takes

Overview

Urges heightened CV safety monitoring in cancer therapy amid FDA constraints; leaves open optimal surveillance strategies.

Key Points

  • The aim is to improve early detection of cardiotoxicity in cancer treatments through innovative strategies and collaborations.
  • Outline public-private partnerships and collaborative oversight models for cardiotoxicity monitoring.
  • Propose a strategic forecasting framework with real-time safety data pipelines and risk mitigation strategies.
  • Utilize AI for signal detection while ensuring human verification of adjudications.
  • Implementation of collaborative models enhances continuous surveillance of cardiac safety during treatment.
  • Establishment of interoperable safety data pipelines improves real-time monitoring of cardiotoxicity.
  • Integration of AI allows for more efficient and effective detection of cardiac signals under regulatory frameworks.

PICO

P
Population
Cardiotoxicity in cancer therapeutics
I
Intervention / Comparator
Artificial intelligence and collaborative models

Proposes a strategic framework leveraging AI, real-world evidence, and public-private partnerships to modernize the detection and surveillance of cardiotoxicity in oncology.

Cite This Study

Richard C. Becker (2026) conducted a review in Cardiotoxicity in cancer therapeutics. Artificial intelligence and collaborative models was evaluated. Artificial intelligence and multi-modality collaborative models can modernize cardiotoxicity detection, protect patients, and sustain benefits in oncology care.

synapsesocial.com/papers/6a1bd1db5783ba022b6fd3fdhttps://doi.org/10.1007/s11239-026-03262-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Advancing cancer therapeutics: new perspectives on mechanisms, regulatory and policy challenges, and innovative multi-modality strategies for the early detection of cardiotoxicity2026
  2. 2Regulatory challenges and current policy for cardiotoxicity detection in oncology drug development2026
  3. 3Artificial intelligence in cardio-oncology: decoding mechanisms, predicting toxicity, and personalizing cancer therapy2026
  4. 4Artificial Intelligence and the Expanding Universe of Cardio-Oncology: Beyond Detection Toward Prediction and Prevention of Therapy-Related Cardiotoxicity—A Comprehensive Review2026 · 3 citations
  5. 5Harnessing artificial intelligence for cardio-oncology:Towards a new future of cardiovascular care for the cancer patient2026 · 3 citations